Blood, marrow, and fat lead to different visits

PRP begins with blood from your arm

PRP is your blood after a machine spins it. The clinic keeps the part holding more small blood pieces called platelets. That blood part is placed near your sore joint or tendon. It is used hoping you'll feel less sore, though relief isn't certain.

Concentrated PRP has a higher amount of those blood pieces. A higher platelet amount doesn't mean better relief. PRP doesn't require taking marrow from your pelvis. Ask what kind they use and why they'd choose it.

BMAC starts with marrow from your pelvis

The letters BMAC refer to pelvic marrow taken for treatment. A machine spins that marrow and keeps a smaller, thicker amount. The clinic then places that spun marrow near the sore joint. This differs from PRP taken at your arm.

The pelvic draw hasn't proved BMAC works better than PRP. Many knee studies found similar changes in soreness and movement. A few smaller studies favored the marrow choice. You'll still want to ask how the clinic handles pelvic soreness afterward.

Fat-based care needs fat taken before treatment

A fat-based choice begins with fat taken from your body. A clinic may break that fat into smaller pieces before using it. The prepared fat is then placed near the sore joint. Ask how they take and prepare it.

Studies haven't shown that taking fat always brings more relief than PRP. The extra procedure can change cost and recovery. Ask why it suits your joint and how many visits follow. A plain answer will name every step.

Home care still comes before a treatment choice

Rest from a hard activity can let an angry joint settle. Gentle movement may keep stiffness from building. Heat or ice can give short relief at home. Don't press on through swelling or sharply worse soreness.

An exam is sensible when those steps don't help enough. Bring any old X-ray plus your medicine list. QC Kinetix offers regenerative treatments, the clinic term for care made from prepared blood or other body material, through medical providers who examine your joint.

Sources

1. The largest head-to-head trial of cell-based orthobiologics to date randomised 480 patients with KL II-IV knee OA across four arms: autologous bone marrow aspirate concentrate, autologous adipose stromal vascular fraction, allogeneic umbilical cord tissue-derived MSCs, and a corticosteroid injection control. At 12 months NONE of the three orthobiologic injections was superior to another or to the corticosteroid control on either co-primary endpoint (VAS pain, KOOS pain), and none of the four groups showed a significant change in MRI osteoarthritis score from baseline. No procedure-related serious adverse events were reported.

   Mautner K, et al. — Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial.. Nature Medicine, 2023. DOI: 10.1038/s41591-023-02632-w.

2. A meta-analysis of 27 Level I studies (1,042 PRP, 226 BMAC, 1,128 HA patients) found significantly better post-injection WOMAC, VAS and subjective IKDC scores for BOTH PRP and BMAC compared with hyaluronic acid - and NO significant difference between PRP and BMAC on any outcome score. This is the clearest published statement that the two most-marketed orthobiologics perform the same as each other in the knee.

   Belk JW, et al. — Patients With Knee Osteoarthritis Who Receive Platelet-Rich Plasma or Bone Marrow Aspirate Concentrate Injections Have Better Outcomes Than Patients Who Receive Hyaluronic Acid: Systematic Review and Meta-analysis.. Arthroscopy, 2023. DOI: 10.1016/j.arthro.2023.03.001.

3. A randomized trial allocated 175 patients with KL II-IV knee OA to BMAC (n=111), PRP (n=34) or hyaluronic acid (n=30) and followed them for 12 months. All three produced significant improvement from baseline in WOMAC, KOOS and IKDC with no serious side effects; BMAC showed significantly better clinical improvement than PRP and HA on most scores, and PRP scored higher than HA without reaching statistical significance. Note the unequal, non-blinded design - this is the strongest direct BMAC-versus-PRP randomized comparison available, and it is not a strong design.

   Dulic O, et al. — Bone Marrow Aspirate Concentrate versus Platelet Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis.. Medicina (Kaunas), 2021. DOI: 10.3390/medicina57111193.

4. In a within-patient placebo-controlled trial, 25 people with BILATERAL knee osteoarthritis received bone marrow aspirate concentrate in one knee and saline in the other, acting as their own controls. Pain scores fell significantly from baseline in BOTH knees at 1 week, 3 months and 6 months, and the relief - described by the authors as dramatic - did not differ significantly between the BMAC knee and the saline knee.

   Shapiro SA, et al. — A Prospective, Single-Blind, Placebo-Controlled Trial of Bone Marrow Aspirate Concentrate for Knee Osteoarthritis.. American Journal of Sports Medicine, 2017. DOI: 10.1177/0363546516662455.

5. A meta-analysis of 6 RCTs (860 patients, 334 receiving BMAC) found overall complication rates of 41.91% for BMAC versus 41.25% for comparator injectables (P=0.85), with knee effusion the commonest BMAC complication at 18.26%. Early and late complication rates did not differ significantly from HA, steroids, PRP, SVF, MSC or saline. The number needed to harm for BMAC relative to other injections was 152.

   Fucaloro S, et al. — Complication rates of bone marrow aspirate concentrate injections versus other injectable therapies for knee osteoarthritis: A systematic review and meta-analysis.. Journal of Orthopaedics, 2025. DOI: 10.1016/j.jor.2024.10.005.

6. A randomized controlled trial compared a SINGLE ultrasound-guided injection of leukocyte-rich PRP (n=30) with micro-fragmented adipose tissue (n=28) in KL 1-4 knee OA. Both groups improved clinically meaningfully from baseline, and there was no significant difference in the primary outcome (KOOS-Pain at 6 months: 80.38 vs 81.61; P=.67) or in any other score - despite MFAT requiring a lipoaspiration procedure and PRP requiring only a blood draw.

   Baria M, et al. — Platelet-Rich Plasma Versus Microfragmented Adipose Tissue for Knee Osteoarthritis: A Randomized Controlled Trial.. Orthopaedic Journal of Sports Medicine, 2022. DOI: 10.1177/23259671221120678.

7. A systematic review of 33 clinical studies of minimally manipulated adipose tissue products for knee OA - of which only 7 were randomized - meta-analysed the 5 RCTs that compared adipose products directly with PRP and found COMPARABLE results between them. The authors explicitly flagged the limits of the literature: few high-level trials and overall low quality.

   Veronesi F, et al. — Adipose Tissue-Derived Minimally Manipulated Products versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Systematic Review of Clinical Evidence and Meta-Analysis.. Journal of Clinical Medicine, 2023. DOI: 10.3390/jcm13010067.

8. A phase III double-blind placebo-controlled trial of a SINGLE injection of culture-expanded autologous adipose-derived MSCs in 261 patients with KL grade 3 knee OA found significantly better VAS pain (25.2 vs 15.5 mm improvement; P=.004) and total WOMAC (21.7 vs 14.3; P=.002) at 6 months versus placebo, with no serious treatment-related adverse events - but MRI showed NO significant difference in cartilage-defect change between groups. Culture-expanded cells of this kind are a drug in the United States and are not available outside a trial.

   Kim KI, et al. — Clinical Efficacy and Safety of the Intra-articular Injection of Autologous Adipose-Derived Mesenchymal Stem Cells for Knee Osteoarthritis: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial.. American Journal of Sports Medicine, 2023. DOI: 10.1177/03635465231179223.

9. The ADIPOA2 phase 2b trial randomised 135 patients with mild-to-moderate knee OA to low-dose (2 million) or high-dose (10 million) culture-expanded autologous adipose-derived stromal cells or saline placebo. At 6 months 47.3% of ADSC patients were OARSI/OMERACT strict responders versus 54.8% on placebo (relative risk 0.86; P=.46), and no secondary outcome differed significantly. A single injection of expanded adipose stromal cells did NOT improve pain or function versus saline.

   Pers YM, et al. — Effect of intra-articular adipose-derived mesenchymal stromal cell versus placebo injection on pain and function in patients with knee osteoarthritis: the ADIPOA2 phase 2b randomised clinical trial.. Annals of the Rheumatic Diseases, 2025. DOI: 10.1016/j.ard.2025.07.026.

10. A phase I/II randomized trial (n=26) compared hyaluronic acid with a single or a repeated dose of culture-expanded umbilical cord-derived MSCs. Only the MSC-treated patients improved significantly from baseline, and the repeated-dose group had significantly lower WOMAC pain (1.1 vs 4.3; P=.04) and VAS pain (2.4 vs 22.1; P=.03) than HA at 12 months. No MRI differences were detected and the trial is very small - it is hypothesis-generating, not practice-changing.

    Matas J, et al. — Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I/II Trial.. Stem Cells Translational Medicine, 2019. DOI: 10.1002/sctm.18-0053.

11. FDA's July 2020 final guidance 'Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use' is the document that decides whether a given orthobiologic can be used without a licence: an HCT/P may be regulated solely under section 361 only if it is minimally manipulated AND intended for homologous use, among other criteria; otherwise it is a drug or biological product requiring an approved licence or an active investigational new drug application.

    U.S. Food and Drug Administration — Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use - Guidance for Industry and Food and Drug Administration Staff. FDA Guidance Document, 2020.